TABLE 2.
Proportions of 11 predominant PFGE profiles identified in eight European countries in the period from 1999 to 2004
| PFGE profile | Cluster/group | Proportion (%) of PFGE profile in the following country and yr:
|
Total no. of isolates | Prevalence (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Finland
|
France
|
Germany
|
The Netherlands
|
Sweden
|
Denmark, 2004 | Poland, 2004 | United Kingdom, 2004 | |||||||||
| 1999 | 2004 | 1999 | 2004 | 1999 | 2004 | 1999 | 2004 | 1999 | 2004 | |||||||
| BpSR11 | IVβ | 5 | 40 | 45 | 50 | 35 | 17 | 30 | 30 | 20 | 35 | 10 | 0 | 45 | 73 | 29 |
| BpSR10 | IVα | 5 | 5 | 10 | 20 | 6 | 6 | 25 | 17 | 0 | 10 | 20 | 0 | 0 | 25 | 10 |
| BpSR5 | IVβ | 5 | 0 | 0 | 0 | 6 | 22 | 15 | 4 | 4 | 5 | 15 | 0 | 15 | 18 | 7 |
| BpSR12 | IVγ | 0 | 0 | 10 | 5 | 6 | 0 | 0 | 4 | 4 | 5 | 25 | 0 | 15 | 15 | 6 |
| BpSR3 | IVα | 0 | 0 | 0 | 10 | 0 | 11 | 0 | 26 | 0 | 0 | 10 | 0 | 0 | 12 | 5 |
| BpSR13 | IVα | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 10 | 0 | 0 | 7 | 3 |
| BpSR16 | IVα | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 0 | 6 | 2 |
| BpSR19 | IVα | 0 | 5 | 0 | 0 | 0 | 0 | 20 | 0 | 4 | 0 | 0 | 0 | 0 | 6 | 2 |
| BpSR7 | IVγ | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 6 | 2 |
| BpSR147 | IVα | 25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 |
| BpSR173 | IVγ | 0 | 0 | 5 | 0 | 0 | 17 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 5 | 2 |
| Total | 55 | 60 | 70 | 85 | 53 | 73 | 90 | 85 | 60 | 80 | 90 | 0 | 75 | |||